On March 25, 2014, Peter N. Kellogg, the Executive Vice President and Chief Financial Officer of Merck & Co., Inc. (NYSE:MRK) and the Company mutually agreed that, effective as of April 23, 2014, Mr. Kellogg’s term as the Company’s Chief Financial Officer would end after seven years of service and significant contributions to the Company. Merck & Co., Inc. (NYSE:MRK) shares after opening at $56.21 moved to $56.96 on last trade day and at the end of the day closed at $55.98. Company price to sales ratio in past twelve months was calculated as 3.74 and price to cash ratio as 9.41. Merck & Co., Inc. (NYSE:MRK) showed a positive weekly performance of 2.41%.
Pfizer Inc. (NYSE:PFE) the world’s largest drugmaker, is testing a PCSK9 inhibitor called bococizumab. Sanofi and Regeneron Pharmaceuticals Inc. are working together on another, called alirocumab. Sanofi and Regeneron expect to seek approval early 2015. Pfizer hasn’t said when it plans to seek approval. Pfizer Inc. (NYSE:PFE) shares fell -0.69% in last trading session and ended the day on $31.88. PFE return on equity ratio is recorded as 52.60% and its return on assets is 23.20%. Pfizer Inc. (NYSE:PFE) yearly performance is 17.64%.
GlaxoSmithKline PLC (NYSE:GSK) on Monday detailed disappointing results from a late-stage study of darapladib, a new heart disease drug. Initial results of the trial were announced by the company in November. GlaxoSmithKline plc (ADR) (NYSE:GSK) shares moved down -0.04% in last trading session and was closed at $53.90, while trading in range of $53.73 – $54.47. GlaxoSmithKline plc (ADR) (NYSE:GSK) year to date (YTD) performance is 2.32%.
AstraZeneca plc (ADR) (NYSE:AZN) and the Medical Research Council (MRC) announced that they have entered into a ground-breaking collaboration aimed at better understanding the mechanisms of human disease. The collaboration will see the creation of a joint research facility at AstraZeneca’s new R&D centre in Cambridge in the UK. AstraZeneca plc (ADR) (NYSE:AZN) weekly performance is 1.65%. On last trading day company shares ended up $65.20. AstraZeneca plc (ADR) (NYSE:AZN) distance from 50-day simple moving average (SMA50) is 0.83%. Analysts mean target price for the company is $67.55.
Leave a Reply